By Dr. Ronald M. BenoitDepartment of Urology, University of Pittsburgh School of Medicine Why would a clinician be hesitant to use Cesium-131 to treat prostate cancer? I would venture to say the likely answer is the data that speaks to its benefits has not yet...
By Dr. Bernard W. TaylorTexas Oncology - Longview Cancer Center The American Cancer Society’s 2022 Cancer Facts and Figures report estimates that nearly 270,000 men will be diagnosed with prostate cancer this year. This represents nearly 50% more than the number of...
By CEO Lori Woods This is my first blog post, and it comes during a year that has changed how we communicate, how we work, and virtually every aspect of our lives. COVID-19 has challenged us and changed us. We hope for better days ahead even as we face the reality of...
At Isoray, we recognize the value of industry conferences, specifically when it comes to continuing your education, staying up-to-date with the latest research, and networking with industry colleagues. Our team is looking forward to once again having the opportunity to join the radiation oncologist community at the ASTRO Annual Meeting to discuss the most recent developments in cancer treatment.
Isoray was proud to be a part of yet another annual meeting for the American Brachytherapy Society (ABS) in Miami and, as we’ve had some time to process all of the stimulating conversations and unique opportunities that ABS always provides, we’d like to highlight some of our favorite moments and discussions from this year’s event.
“I urge newly diagnosed men to see a range of specialists before selecting treatment. After talking to a urologist, they should make independent appointments with a radiation oncologist, a medical oncologist, and a brachytherapist to ensure that they become fully...
As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types.
Building community around the power of Cesium The radiation oncologist community is one of the cornerstones on which we are building the future of brachytherapy at Isoray. As such, in person engagements at the ASTRO Annual Meeting are some of our most important...
The International Journal of Radiation Oncology recently published a study titled Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer.
Dr. Bradley Prestidge, MD, MS, serves as Regional Medical Director of Radiation Oncology for Bon Secours Medical Group in Norfolk, Va. During the American Brachytherapy Society 2018 Annual Meeting, Dr. Prestidge shared with us his opinion on brachytherapy’s top...
Capitalizing on the same value ASTRO provides for radiation oncologists to connect with peers in a concentrated way, we invite the entire community to visit the Isoray team at ASTRO 2018.
In a new study, radiation oncologists find that DR-BT is not only feasible, but also highly effective in men with cT3a and cT3b high-risk prostate cancer.